BBNX — Beta Bionics, Inc.
$19.16-0.93%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for BBNX in the TickerWise workspace.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Company profile
- Sector: Healthcare
- Industry: Medical - Equipment & Services
- Country: US
- Exchange: NASDAQ
- Employees: 352
- Website: https://www.betabionics.com
Latest SEC filings for BBNX
Latest BBNX news
- BBNX DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX Read article
- BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit Read article
- BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Read article
- BBNX DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX Read article
- Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm Read article
- BBNX Shareholder Alert: Beta Bionics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky Read article
- BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit Read article
- BBNX DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.